Clear Creek Bio Advances Its Highly Potent SARS-CoV-2 PLpro Inhibitors in Discovery of an Oral Direct-Acting Antiviral to Treat COVID-19
- Clear Creek Bio signed a CRADA with the NIH to support its SARS-CoV-2 PLpro inhibitor discovery
- This CRADA was initiated as part of the Antiviral Program for Pandemics (APP)
- Via APP, Clear Creek will be able to use the NIH’s current and expanded contract resources and NCATS laboratories to prioritize the advancement of antiviral candidates and de-risk early-stage development
Excerpt from the Press Release:
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Clear Creek Bio, Inc. announced today that the company has signed a Cooperative Research and Development Agreement (CRADA) with the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) to identify and develop a SARS-CoV-2 papain-like protease (PLpro) inhibitor. PLpro is an essential coronavirus enzyme involved in viral replication and regulates host innate immune responses to viral infection. The potent PLpro inhibitors developed by Clear Creek Bio have attractive drug properties, and this CRADA will support development of the most promising candidates, including completing IND-enabling studies.
“PLpro is a promising target for therapeutic intervention against COVID-19 because of its potential for dual effects—blocking SARS-CoV-2 replication and promoting antiviral immunity,” said Vikram Sheel Kumar, M.D., Chief Executive Officer of Clear Creek Bio. “We have potent inhibitors that we are excited to advance and expand under this collaboration with NCATS.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?